
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trials of AL001
Alzamend Neuro collaborates with Massachusetts General Hospital to conduct Phase II clinical trials of AL001, a potential breakthrough treatment for bipolar disorder and Alzheimer's disease. The trials aim to compare AL001's efficacy and safety to existing lithium treatments, potentially revolutionizing mental health care.
Read full story























